Optimistic Growth Outlook for Jazz Pharmaceuticals Amid Strategic Product Focus and Pipeline Catalysts

Analyst Ami Fadia of Needham maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), boosting the price target to $200.00.

Ami Fadia has given his Buy rating due to a combination of factors that suggest potential growth for Jazz Pharmaceuticals. Despite the first quarter earnings per share falling short of expectations, the company has shown resilience with its strategic focus on key products. The minimal impact of tariffs in 2025 is a positive sign, although there remains some uncertainty for the years beyond.
Jazz Pharmaceuticals is experiencing growth in its Xywav product, particularly in the narcolepsy and idiopathic hypersomnia markets. Additionally, the company anticipates several pipeline catalysts that could drive future momentum, including upcoming data releases for Zani, Zepzelca, and Dordaviprone. These developments, alongside expected improvements in oncology sales and Rylaze performance, underpin the optimistic outlook for the company’s stock.

According to TipRanks, Fadia is a 2-star analyst with an average return of 0.0% and a 41.87% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Jazz Pharmaceuticals, and Biogen.

In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $166.00 price target.